Peter E. Boyd is CPO at Aquestive Therapeutics, Inc. (AQST). They have made 6 open-market trades across 1 company since 2018, most recently 2026-09-09.
CIK 0001739816
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $14K since 2018, against 1 sale. Across 5 scored buys the stock is up 77.5% at ninety days, and 66.7 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AQST | 284,024 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-10 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 40% | 80% |
| Avg Move | -1.4% | +16.6% | +77.5% |
| Alpha | -3.3% | +12.2% | +66.7% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AQST | SELL | 2026-03-10 | 2026-03-11 | $4.17 | $124K | -7.5% | -4.0% | -5.8% |
| AQST | SELL · 10b5-1 | 2025-10-15 | 2025-10-17 | $7.00 | $70K | -10.0% | -19.2% | -53.6% |
| AQST | SELL · 10b5-1 | 2025-09-26 | 2025-09-29 | $6.30 | $63K | +19.5% | +15.7% | +15.5% |
| AQST | SELL · 10b5-1 | 2025-09-05 | 2025-09-08 | $5.30 | $80K | +1.0% | +26.8% | +35.4% |
| AQST | BUY | 2022-06-14 | 2022-06-15 | $0.81 | $4K | -14.9% | +1.1% | +60.5% |
| AQST | BUY | 2022-06-08 | 2022-06-10 | $0.96 | $2K | -15.5% | -8.9% | +63.3% |
| AQST | BUY | 2020-03-16 | 2020-03-18 | $1.50 | $3K | +45.5% | +132.7% | +239.7% |
| AQST | BUY | 2019-08-12 | 2019-08-13 | $3.81 | $2K | +1.0% | -5.8% | +57.1% |
| AQST | BUY | 2018-11-21 | 2018-11-26 | $9.98 | $2K | -23.0% | -36.1% | -33.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.